Hyperinsulinemia and ectopic fat deposition can develop in the face of hyperadiponectinemia in young obese rats

Journal of Nutritional Biochemistry

Volumn 22, Issue 2, 2011, Pages 142-152

  Marecki, John C ^a,b   Ronis, Martin J J ^a,b   Shankar, Kartik ^a,b   Badger, Thomas M ^a,b  

^a U S DEPARTMENT OF AGRICULTURE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Adiponectin; FAT CD36; High fat; Non alcoholic fatty liver disease; Pediatric obesity; Total enteral nutrition

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; FATTY ACID; FATTY ACID TRANSPORTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; CALORIC INTAKE; CHILDHOOD DISEASE; CONTROLLED STUDY; DIETARY INTAKE; DYSLIPIDEMIA; ENTERIC FEEDING; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FATTY LIVER; GENE EXPRESSION; HISTOPATHOLOGY; HYPERADIPONECTINEMIA; HYPERINSULINEMIA; LIPID DIET; LIPID STORAGE; LIVER; MALE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OVERNUTRITION; PROTEIN PHOSPHORYLATION; RAT; SEROLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TISSUE SPECIFICITY;

ADIPONECTIN; ADIPOSE TISSUE; ADIPOSITY; AGE FACTORS; ANIMALS; ANTIGENS, CD36; ENTERAL NUTRITION; FATTY LIVER; HYPERINSULINISM; LIPID METABOLISM; MALE; OBESITY; OVERNUTRITION; RATS; RATS, SPRAGUE-DAWLEY; WEIGHT GAIN;

RATTUS;

EID: 78651236375     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2010.01.001     Document Type: Article

References (51)

1. Papandreou D., Rousso I., Mavromichalis I. Update on non-alcoholic fatty liver disease in children. Clin Nutr 2007, 26:409-415.
2. Johnson L., Mander A.P., Jones L.R., Emmett P.M., Jebb S.A. Energy-dense, low-fiber, high-fat dietary pattern is associated with increased fatness in childhood. Am J Clin Nutr 2008, 87:846-854.
3. McNaughton S.A., Ball K., Mishra G.D., Crawford D.A. Dietary patterns of adolescents and risk of obesity and hypertension. J Nutr 2008, 138:364-370.
4. Syrenicz A., Garanty-Bogacka B., Syrenicz M., Gebala A., Walczak M. Low-grade systemic inflammation and the risk of type 2 diabetes in obese children and adolescents. Neuro Endocrinol Lett 2006, 27:453-458.
5. Aeberli I., Beljean N., Lehmann R., I'Allemand D., Spinas G.A., Zimmermann M.B. The increase of fatty acid-binding protein aP2 in overweight and obese children: interactions with dietary fat and impact on measures of subclinical inflammation. Int J Obes (Lond) 2008, 32:1513-1520.
6. Schwimmer J.B., Behling C., Newbury R., Deutsch R., Nievergelt C., Schork N.J., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005, 42:641-649.
7. Schwimmer J.B. Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents. Semin Liver Dis 2007, 27:312-318.
8. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
9. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332-339.
10. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends in Endocrinol. Metab. 2003, 14:137-145.
11. Nawrocki A.R., Rajala M.W., Tomas E., Pajvani U.B., Saha A.K., Trumbauer M.E., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2006, 281:2654-2660.
12. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91-100.
13. Kim J.Y., van de W.E., Laplante M., Azzara A., Trujillo M.E., Hofmann S.M., et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007, 117:2621-2637.
14. Punthakee Z., Delvin E.E., O'loughlin J., Paradis G., Levy E., Platt R.W., et al. Adiponectin, adiposity, and insulin resistance in children and adolescents. J Clin Endocrinol Metab 2006, 91:2119-2125.
15. Asayama K., Hayashibe H., Dobashi K., Uchida N., Nakane T., Kodera K., et al. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res 2003, 11:1072-1079.
16. Kern P.A., Di Gregorio G.B., Lu T., Rassouli N., Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-α expression. Diabetes 2003, 52:1779-1785.
17. Imhof A., Kratzer W., Boehm B., Meitinger K., Trischler G., Steinbach G., et al. Prevalence of non-alcoholic fatty liver and characteristics in overweight adolescents in the general population. Eur J Epidemiol 2007, 22:889-897.
18. Cianflone K., Lu H., Smith J., Yu W., Wang H. Adiponectin, acylation stimulating protein and complement C3 are altered in obesity in very young children. Clin Endocrinol (Oxf) 2005, 62:567-572.
19. Rodriguez A., Catalan V., Becerril S., Gil M.J., Mugueta C., Gomez-Ambrosi J., et al. Impaired adiponectin-AMPK signaling in insulin-sensitive tissues of hypertensive rats. Life Sci 2008, 83:540-549.
20. Bullen J.W., Bluher S., Kelesidis T., Mantzoros C.S. Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. Am J Physiol Endocrinol Metab 2007, 292:E1079-E1086.
21. Semple R.K., Halberg N.H., Burling K., Soos M.A., Schraw T., Luan J., et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes 2007, 56:1712-1717.
22. Memon R.A., Fuller J., Moser A.H., Smith P.J., Grunfeld C., Feingold K.R. Regulation of putative fatty acid transporters and Acyl-CoA synthetase in liver and adipose tissue in ob/ob mice. Diabetes 1999, 48:121-127.
23. Koonen D.P., Jacobs R.L., Febbraio M., Young M.E., Soltys C.L., Ong H., et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 2007, 56:2863-2871.
24. Holloway G.P., Luiken J.J., Glatz J.F., Spriet L.L., Bonen A. Contribution of FAT/CD36 to the regulation of skeletal muscle fatty acid oxidation: an overview. Acta Physiol (Oxf) 2008, 194:291-309.
25. Boden G., Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in development of insulin resistance and beta cell dysfunction. Eur J Clin Invest 2002, 32:14-23.
26. Crossland H., Constantin-Teodosiu, Gardiner S.M., Constantin D., Greenhaff P.L. A potential role for Akt/FOXO signaling in both protein loss and the impairment of muscle carbohydrate oxidation during sepsis in rodent skeletal muscle. J Physiol 2008, 586:5589-5600.
27. Gross D.N., Wan M., Birnbaum M.J. The role of FOXO in the regulation of metabolism. Curr. Diabetes Rep 2009, 9:208-214.
28. Matsumoto M., Han S., Kitamura T., Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest 2006, 116:2464-2472.
29. Ronis M.J., Butura A., Sampey B.P., Shankar K., Prior R.L., Korourian S., et al. Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. Free Radic Biol Med 2005, 39:619-630.
30. McGloin A.F., Livingstone M.B., Greene L.C., Webb S.E., Gibson J.M., Jebb S.A., et al. Energy and fat intake in obese and lean children at varying risk of obesity. Int J Obes Relat Metab Disord 2002, 26:200-207.
31. Baumgardner J.N., Shankar K., Hennings L., Badger T.M., Ronis M.J. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol 2008, 294:G27-G38.
32. Deng Q.G., She H., Cheng J.H., French S.W., Koop D.R., Xiong S., et al. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 2005, 42:905-914.
33. Ota T., Takamura T., Kurita S., Matsuzawa N., Kita Y., Uno M., et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007, 132:282-293.
34. Matsuzaki H., Daitoku H., Hatta M., Tanaka K., Fukamizu A. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci U S A 2003, 100:11285-11290.
35. Araki S., Dobashi K., Kubo K., Yamamoto Y., Asayama K. Shirahata A. N-acetylcysteine attenuates TNF-α induced changes in secretion of interleukin-6, plasminogen activator inhibitor-1 and adiponectin from 3T3-L1 adipocytes. Life Sci 2006, 79:2405-2412.
36. Hawley S.A., Davison M., Woods A., Davies S.P., Beri R.K., Carling D., et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 1996, 271:27879-27887.
37. Garcia-Ruiz I., Rodriguez-Juan C., Diaz-Sanjuan T., Martinez M.A., Munoz-Yague T., Solis-Herruzo J.A. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology 2007, 46:414-423.
38. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
39. Spranger J., Kroke A., Mohlig M., Bergmann M.M., Ristow M., Boeing H., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361:226-228.
40. Brooks N.L., Moore K.S., Clark R.D., Perfetti M.T., Trent C.M., Combs T.P. Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome?. Diabetes Obes Metab 2007, 9:246-258.
41. Winer J.C., Zern T.L., Taksali S.E., Dziura J., Cali A.M., Wollschlager M., et al. Adiponectin in childhood and adolescent obesity and its association with inflammatory markers and components of the metabolic syndrome. J Clin Endocrinol Metab 2006, 91:4415-4423.
42. Barnea M., Shamay A., Stark A.H., Madar Z. A high-fat diet has a tissue-specific effect on adiponectin and related enzyme expression. Obesity (Silver Spring) 2006, 14:2145-2153.
43. Varanasi U., Chu R., Huang Q., Castellon R., Yeldandi A.V., Reddy J.K. Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem 1996, 271:2147-2155.
44. Minnich A., Tian N., Byan L., Bilder G. A potent PPAR-α agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2001, 280:E270-E279.
45. Yoon M.J., Lee G.Y., Chung J.J., Ahn Y.H., Hong S.H., Kim J.B. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor-α. Diabetes 2006, 55:2562-2570.
46. Whitehead J.P., Richards A.A., Hickman I.J., Macdonald G.A., Prins J.B. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006, 8:264-280.
47. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
48. Guo W., Pirtskhalava T., Tchkonia T., Xie W., Thomou T., Han J., et al. Aging results in paradoxical susceptibility of fat cell progenitors to lipotoxicity. Am J Physiol Endocrinol Metab 2007, 292:E1041-E1051.
49. He L., Marecki J.C., Serrero G., Simmen F.A., Ronis M.J.J., Badger T.M. Dose-dependent effects of alcohol on insulin signaling: Partial explanation for biphasic alcohol impact on human health. Mol Endocrinol 2007, 21:2541-2550.
50. Altomonte J., Richter A., Harbaran S., Suriawinata J., Nakae J., Thung S.N., et al. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab 2003, 285:E718-E728.
51. Samuel V.T., Choi C.S., Phillips T.G., Romanelli A.J., Geisler J.G., Bhanot S., et al. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 2006, 55:2042-2050.